MMS

MMS is an award-winning, global clinical research organization (CRO) that supports leading pharmaceutical and biotech companies as well as smaller enterprises. With over 50 submissions for drug approval in the last 5 years, it remains a top choice for sponsors seeking innovation and high quality. The senior leadership boasts over two decades of hands-on drug development experience, supporting program-level strategy and project execution across multiple therapeutic areas.

Continual staff training, innovative recruitment, and motivating career opportunities contribute to MMS's ability to retain top talent and develop a client-focused workforce across all global locations. Established in 2006 and headquartered in the United States, MMS recently secured a Private Equity Round investment on 28 June 2022 from Lindsay Goldberg.

MMS focuses on delivering high-quality services rooted in good science and decades of regulatory experience to assist clients in developing and marketing life-changing therapies, positively affecting patients' lives worldwide within the Biotechnology and Health Care industries.